{"entity":{"id":"tnfrsf4","kind":"target","name":"OX40 (TNFRSF4)","aka":["OX40","CD134","ACT35","TNF receptor superfamily member 4"],"tldr":"OX40 is an accelerator that appears on T cells once they are switched on; pressing it makes them multiply and survive longer. Agonist antibodies against it are in trials, including a phase 3 in head and neck cancer.","summary":"TNFRSF4 (chromosome 1p36.33) encodes OX40, the receptor for OX40 ligand (TNFSF4) and a costimulatory molecule implicated in long-term T-cell immunity (UniProt P43489). OX40 ligation augments CD4 and CD8 T-cell clonal expansion, effector differentiation and survival, and in some cases abrogates the suppressive activity of regulatory T cells (Croft 2009, Immunol Rev). INBRX-106, a hexavalent OX40 agonist antibody, is in a phase 2/3 study with pembrolizumab in first-line PD-L1-high head and neck squamous cell carcinoma (NCT06295731).","asOf":"2026-09-24","links":[{"label":"HGNC HGNC:11918","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11918"},{"label":"UniProt P43489","url":"https://www.uniprot.org/uniprotkb/P43489/entry"},{"label":"NCBI Gene 7293","url":"https://www.ncbi.nlm.nih.gov/gene/7293"},{"label":"Croft 2009, Immunol Rev (Europe PMC)","url":"https://europepmc.org/article/MED/19538134"}],"tags":["checkpoint-map"],"related":["cd137","tnfrsf18","pembrolizumab"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["inbrx-106"],"companies":[],"institutions":[],"pathways":["cancer-immunity-cycle"],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Prevalence not recorded: HGNC and UniProt carry no positivity rates."],"provenance":{"editedBy":"OnCo checkpoint map (HGNC REST, UniProt REST, ClinicalTrials.gov v2)","editedOn":"2026-09-24"},"symbol":"TNFRSF4","role":["immune-checkpoint"],"sources":[{"label":"HGNC HGNC:11918","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11918","note":"approved symbol, name, aliases and cross-references"},{"label":"UniProt P43489","url":"https://www.uniprot.org/uniprotkb/P43489/entry","note":"protein name, function and tissue specificity"}],"specificitySources":[],"hgnc":"HGNC:11918","ensembl":"ENSG00000186827","uniprot":"P43489","entrez":"7293","biology":"A TNF-receptor-superfamily costimulator induced on activated T cells; agonists need receptor clustering, which is why hexavalent formats are tried.","whereFound":["Activated T cells (Croft 2009)","Head and neck squamous cell carcinoma trial of INBRX-106 (NCT06295731)"],"targetClass":"surface-antigen","prevalence":[]},"route":"/targets/tnfrsf4/","neighbours":{"target":[{"id":"cd137","kind":"target","name":"CD137 (4-1BB, TNFRSF9)","route":"/targets/cd137/"},{"id":"tnfrsf18","kind":"target","name":"GITR (TNFRSF18)","route":"/targets/tnfrsf18/"}],"drug":[{"id":"inbrx-106","kind":"drug","name":"INBRX-106","route":"/drugs/inbrx-106/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"pathway":[{"id":"cancer-immunity-cycle","kind":"pathway","name":"The cancer-immunity cycle","route":"/pathways/cancer-immunity-cycle/"}],"term":[{"id":"checkpoint","kind":"term","name":"Checkpoint (two meanings)","route":"/terms/checkpoint/"}]}}